2-氯-5-氰基苯硼酸 | 936249-33-1

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氯-5-氰基苯硼酸
• 中文别名: 2-氯-5-氰苯硼酸；1-乙氧基-2-三丁基锡乙烯
• 英文名称: (2-chloro-5-cyanophenyl)boronic acid
• 英文别名: 2-chloro-5-cyanophenyl boronic acid；2-chloro-5-cyanophenylboronic acid
• CAS: 936249-33-1
• 化学式: C₇H₅BClNO₂
• mdl: MFCD06656271
• 分子量: 181.386
• InChiKey: YNZXUVCJPQNYHR-UHFFFAOYSA-N

物化性质

• 沸点：
  370.8±52.0 °C(Predicted)
• 密度：
  1.41±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.97
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  64.2
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2931900090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Chloro-5-cyanophenylboronic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Chloro-5-cyanophenylboronic acid
CAS number: 936249-33-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H5BClNO2
Molecular weight: 181.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氯-5-氰基苯硼酸 在 bis-triphenylphosphine-palladium(II) chloride 、 tris-(dibenzylideneacetone)dipalladium(0) 、 potassium acetate 、 sodium carbonate 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 1,4-二氧六环 、 乙二醇二甲醚 、 水 为溶剂， 生成 (R)-6-(3-(3-(3-(1H-benzo[d]imidazol-2-yl)morpholino)-3-oxopropyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-[1,1'-biphenyl]-3-carbonitrile
  参考文献：
  名称：

  氮杂吲哚作为JAMM蛋白酶CSN5的锌结合小分子抑制剂

  摘要：

  CSN5是COP9信号小体（CSN）的锌金属蛋白酶亚基，是cullin-RING E3泛素连接酶（CRL）的重要调节剂。CSN5负责从CRL中裂解NEDD8，而阻断NEDD8的脱共轭作用则使CRL处于高活性状态，从而导致自身泛素化并最终降解了底物识别亚基。在这里，我们描述了氮杂吲哚的发现，它是一类新型的CSN5抑制剂，它们以前所未有的结合方式与CSN5的活性位锌离子相互作用。最好的化合物以纳摩尔浓度抑制CSN5，导致细胞中底物识别亚基Skp2降解，并降低HCT116细胞的生存能力。

  DOI：

  10.1002/anie.201608672

文献信息

• [EN] SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASE INHIBITORS<br/>[FR] PYRIMIDINYLPYRROLES SUBSTITUÉS ACTIFS EN TANT QU'INHIBITEURS DE KINASES
  申请人：NERVIANO MEDICAL SCIENCES SRL

  公开号：WO2012143248A1

  公开（公告）日：2012-10-26

  The present invention relates to substituted pyrimidinyl-pyrrole compounds of formula (I) which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular Janus kinases. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such compounds or the pharmaceutical compositions containing them.

  本发明涉及式(I)的取代嘧啶基-吡咯烷化合物，其调节蛋白激酶的活性，因此在治疗由失调的蛋白激酶活性引起的疾病方面具有用处，特别是Janus激酶。本发明还提供了制备这些化合物的方法，包括这些化合物的药物组合物，以及利用这些化合物或含有它们的药物组合物治疗疾病的方法。
• ANTIPROLIFERATION COMPOUNDS AND USES THEREOF
  申请人：Merck Patent GmbH

  公开号：US20190322658A1

  公开（公告）日：2019-10-24

  The present invention provides compounds of Formula I′, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).

  本发明提供了式I′的化合物，或其药学上可接受的盐，以及用于治疗细胞增殖性疾病（例如癌症）的药物组合物和使用方法。
• Ligandless Nickel-Catalyzed <i>Ortho</i>-Selective Directed Trifluoromethylthiolation of Aryl Chlorides and Bromides Using AgSCF₃
  作者：Tin Nguyen、Weiling Chiu、Xinying Wang、Madeleine O. Sattler、Jennifer A. Love

  DOI：10.1021/acs.orglett.6b02689

  日期：2016.11.4

  A mild protocol for Ni-catalyzed trifluoromethylthiolation of aryl chlorides and bromides is described herein. The method utilizes AgSCF3 as an easily accessible nucleophilic trifluoromethylthiolating reagent and does not require any ligands or additives. Ortho-selectivity is achieved using a variety of directing groups such as imines, pyridines, and oxazolines for 24 examples in up to 95% yield.

  本文描述了Ni催化的芳基氯化物和溴化物的三氟甲基硫醇化的温和方案。该方法利用AgSCF 3作为容易获得的亲核三氟甲基硫醇化试剂，不需要任何配体或添加剂。对于24个实例，使用多种指导基团如亚胺，吡啶和恶唑啉实现邻位选择性，产率高达95％。
• Chiral Atropisomeric Indenocorannulene Bowls: Critique of the Cahn–Ingold–Prelog Conception of Molecular Chirality
  作者：Yujia Wang、Oliver Allemann、T. Silviu Balaban、Nicolas Vanthuyne、Anthony Linden、Kim K. Baldridge、Jay S. Siegel

  DOI：10.1002/anie.201801325

  日期：2018.5.28

  phases motivates the study of chiroptical properties, the assignment of absolute “Cartesian” configuration, and the assessment of configurational stability.7 These studies bring into question any systematic assignment of nontrivial stereoelements (i.e. not the molecule in its entirety) and refute any assertion of congruence between “Cahn–Ingold–Prelog elements” and the physical or “Cartesian” basis of

  手性Corannulenes比比皆是，但通常会遭受碗到碗倒置相关的构型不稳定性1，从而避免了立体性和立体元素构造的问题。2相反，围成环的Corannulenes显示碗对碗倒置的障碍大大增加。特别是茚并环戊二烯的转化时间太慢，无法通过常规NMR方法观察到，并增加了产生手性阻转异构碗形芳烃的可能性。3两种由简单的2-卤代芳基Corannulenes制备茚并蒽环的方法-甲硅烷基阳离子C-F活化，4和Pd介导的C-Cl活化[5]-使得能够合成这类手性阻转异构体茚并蒽环。6通过高效液相色谱在手性支持相上拆分对映异构体，促进了对手性性质，绝对“笛卡尔”构型的分配以及构型稳定性的评估的研究。7这些研究对非平凡的立体元素的任何系统分配（即不是分子整体）提出了质疑，并驳斥了“ Cahn–Ingold–Prelog元素”与手性的物理或“笛卡尔”基础之间的任何一致性主张。
• NOVEL IMIDAZOLIDINE DERIVATIVES
  申请人：Dehmlow Henrietta

  公开号：US20090312382A1

  公开（公告）日：2009-12-17

  The invention is concerned with novel imidazolidine derivatives of formula (I) wherein R 1 to R 3 , A, D and E are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds bind to LXR alpha and LXR beta and can be used as medicaments.

  该发明涉及式（I）的新型咪唑啉衍生物，其中R1至R3，A，D和E如描述和权利要求中所定义，并且其生理上可接受的盐和酯。这些化合物与LXRα和LXRβ结合，并可用作药物。